Study Objectives: A baseline/1-hour rule-in/rule-out acute myocardial infarction (AMI) algorithm using cardiac troponin T Generation 5 (cTnT Gen 5) measurements is detailed in the 2015 European Society of Cardiology (ESC) non-ST-elevation myocardial infarction (NSTEMI) guidelines. The accuracy of the positive and negative predictive values for diagnostic testing plays a key role in physician therapeutic decisionmaking, especially for acutely ill patients.
To determine the ESC recommended baseline/1 hour AMI rule-in (hs-cTnT at 0-hour > 52 or a 1-hour delta 5 ng/L) positive predictive value (PPV) in the REACTION-US (Rapid evaluation of acute myocardial infarction in the United States) study and to compare it to that reported in the TRAPID-AMI (High sensitivity cardiac troponin T assay for rapid rule-out of acute myocardial infraction) international multicenter trial.
Methods: Patients presenting with any symptoms, regardless of duration, suspicious for an acute coronary syndrome (ACS) to the emergency department (ED) of a single US tertiary care urban center were enrolled. Baseline (within 60 minutes of triage ECG) and 1-hour blood samples were obtained and later analyzed for cTnT Gen 5 (Roche Diagnostics: 99 th percentile 14 ng/L, level of detection 5 ng/L) measurements at an independent core laboratory. AMI diagnosis was independently adjudicated by 2 physicians after reviewing all available 30-day clinical data and the hospital's serial cardiac troponin I (Siemens: 99 th percentile 40 ng/L) levels over 3 hours in accordance with the 3 rd Universal Definition of AMI. Results: Of the 569 enrolled subjects 44 (7.7%) had AMI: 26 type 1 (59%) and 18 (41%) type 2. After analyzing the baseline/1-hour ESC rule-in algorithm in the 542 patients with cTnT Gen 5 values available at both times, 69 (12.7%) were placed in the AMI rule-in zone. The resulting 1-hour AMI rule-in PPV was 42.0% (95% CI: 30.2%-54.5%). In the TRAPID-AMI trial 184 (14.4%) patients were placed in the rule-in zone and with a 1-hour AMI rule-in PPV of 77.2% (95% CI: 70.4%-83.0%). The PPV for the 1-hour rule-in AMI was significantly lower (p < 0.001) in the US ED population.
Conclusions: The PPV was significantly lower when the ESC guidelines AMI 1-hour rule-in were applied to the REACTION-US study as compared to the TRAPID-AMI international trial. This was likely the result of broader troponin ordering and enrollment of some dialysis patients, which may have resulted in an increased overall number of elevated cTnT Gen 5 measurements. The current ESC 1-hour rule-in AMI guidelines PPVs are inadequate to initiate early NSTEMI therapy in US and international ED patients as many individuals will receive unnecessary anticoagulation/ additional cardiac testing. Further studies are needed to determine the optimal cut points/blood draw timing for a rapid AMI rule-in guideline resulting in higher PPVs.
Diagnostic Accuracy of Adding Copeptin to Cardiac Troponin for Non-ST-Elevation Myocardial Infarction: A Systematic Review and MetaAnalysis
Kim C, Lim T, Kim W, Shin H, Na S/Hanyang University, Seoul, Korea, Republic of; Hallym University, Seoul, Republic of Korea Study Objectives: This study aimed to determine the diagnostic accuracy of adding copeptin to cardiac troponin (cTn) on admission to the emergency department (ED) for non-ST elevation myocardial infarction (NSTEMI) compared to cTn alone.
Methods: A literature search of MEDLINE, EMBASE, and the Cochrane Library was performed (search date: April 13, 2018). Primary studies were included if they accurately reported on patients with symptoms suggestive of acute myocardial infarction and measured both cTn alone and cTn with copeptin upon admission to the ED. The patients with evidence of ST elevation myocardial infarction were excluded. To assess the risk of bias for the included studies, the QUADAS-2 tool was used.
Results: The study participants included a total of 7,998 patients from 14 observational studies. The addition of copeptin to cTn significantly improved the sensitivity (0. Conclusions: Adding copeptin to cTn improved the sensitivity and negative predictive value for the diagnosis of NSTEMI compared to cTn alone. Thus, adding copeptin to cTn might help to screen NSTEMI early upon admission to the ED. Study Objectives: The 30 day Major Adverse Cardiac Event (MACE) rate after implementation of a chest pain rapid rule out (CP RRO) process utilizing the new generation 5 high sensitivity troponin T (hs-TnT) is currently not known. Our objective was to compare the rate of patients returning to our health system with MACE within 30 days of low risk discharge from an emergency department (ED) visit for potential acute coronary symptoms before and after implementation of the process.
Methods: The CP RRO process was implemented in step-wise fashion at 11 hospital-based EDs and 3 freestanding EDs between 7/6/17 and 2/18/18. Process was initiated either at triage or by attending provider. Initial hs-TnT was drawn on arrival, with repeat obtained 1 hour later and at least 3 hours post onset of pain. Patients were identified as low risk after meeting all of the following: no high risk history (unstable angina), no new ECG changes, modified HEART score (age + risk factors only) < 4, initial hs-TnT < 12 ng/l, and 1 hour delta hs-TnT < 3 ng/l. Clinical decision support was embedded into the electronic health record (EHR, EPIC) and decision trees were posted to aid interpretation. Final disposition was at the discretion of the attending physician. All encounters where patients had at least 2 troponins (either TnT or hsTnT) obtained during an ED or ED and hospital visit were entered into a quality database from Clarity database by Business Intelligence. The presence of acute myocardial infarction (AMI), percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), and mortality within 30 days of discharge was recorded. Procedures were identified as planned if there was prior notation in the EHR or in the history of present illness of the index visit. Mortality were reviewed and classified by likely cause of death without knowledge of whether CP RRO process was utilized.
Results: A total of 2914, 4986, and 3614 patients were discharged in 2016, 2017, and 2018, respectively. The composite 30 day MACE rate was 0.30%, 0.28%, and 0.14%, respectively. This decreased to 0.069%, 0.100%, and 0.028%, respectively, when planned PCI and CABG as well as expected mortality were removed. The AMI 30 day MACE rate was 0.034%, 0%, and 0.014%
Within the CP RRO patients, there was 1 NSTEMI, who subsequently underwent CABG within 30 days. There was 1 planned PCI and 3 planned CABGs. The 12 mortalities were classified as 0 cardiovascular; 6 DNR/palliative/hospice; 1 oncologic respiratory failure; 1 post operative complication; 1 opioid substance abuse; and 3 unknown etiologies. One of the unknown mortalities occurred after discharge with CP RRO.
Conclusions: Use of our CP RRO process utilizing hs-TnT is associated with a very low rate of major adverse cardiac events in patients returning within 30 days to our health system. Methods: This study is a pre-specified secondary analysis of a prospective, observational trial (NCT01802398) conducted across 11 academic hospital EDs in the US, enrolling patients 60 yrs presenting with syncope or near syncope between 4/ 2013-9/2016. Patients were excluded if they presented with seizure, stroke, transient ischemic attack, trauma, intoxication, hypoglycemia or had persistent confusion, required mechanical/electrical intervention, lacked phone access or a permanent address, or did not speak English or Spanish. Within 3 hours of informed consent HscTnT and NT-proBNP samples were collected and later analyzed in a central laboratory using Roche Elecsys Gen 5 STAT® and 2010 Cobas® respectively. Results were analyzed in all patients who had at least 1 biomarker against our primary outcome of all 30-day serious cardiac outcomes and all-cause mortality. We used multivariate logistic regression models to estimate the association between the primary outcome and biomarker levels, adjusting for measures of illness severity. We estimated adjusted absolute risk associated with ranges of biomarker levels using Bayesian Markov Chain Monte Carlo. Likelihood ratios and predictive values were calculated.
Results: Of 3,392 patients 367 (10.8%) patients experienced the primary outcome. Adjusted absolute risk for the primary outcome increased as a function of both hs-cTnT and NT-pro BNP levels. Hs-cTnT level 5 ng/L were associated with a 4% (95CI: 3-
